We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

By LabMedica International staff writers
Posted on 20 Oct 2026

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More...

More than 500 of these rare disorders are known, leaving affected children vulnerable to infection, allergies, inflammation, autoimmunity, and cancer. Delayed or duplicated testing can add stress for families and slow treatment decisions. New findings now show that a streamlined genetic testing model could substantially shorten the time to diagnosis.

University of Queensland (Brisbane, Australia) researchers, working with Children’s Health Queensland, evaluated a new model of care for genomic testing in pediatric inborn errors of immunity. The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. Under the model, diagnosis waiting times could fall from 12 months to as little as two weeks.

The study examined nine years of genetic test data from 322 children tested through Queensland’s pediatric immunology service. Researchers assessed how the new testing process could improve testing rates and reduce unnecessary procedures. The analysis found that 30% of cases involved duplicate blood tests that were not needed.

The findings also showed that once a genetic diagnosis was made, the treatment plan changed in 90% of cases. Treatments for these conditions can include stem cell transplants, blood antibody infusions or infection prevention, depending on the condition. The study, “Evaluating Genomic Testing in Pediatric Inborn Errors of Immunity: An Optimal Model of Care,” was published in the Journal of Clinical Immunology.

The model also incorporates multidisciplinary team meetings in which specialists share knowledge on patient cases. According to Queensland Children’s Hospital, this structure reduces the need for families to move between multiple specialists. The study was conducted by the University of Queensland and Children’s Health Queensland.

“A faster result and diagnosis mean we can start targeted treatments early, which leads to fewer cumulative problems and less organ damage and increases the chance of kids leading a more normal life and attending school rather than being in and out of the hospital,” said Dr. Peter McNaughton, immunologist at Queensland Children’s Hospital.

“We regularly hold multidisciplinary team meetings where all specialists involved share knowledge on patient cases, which in turn allows everyone to improve their skills and cuts out the need for patients to be referred to several different specialists. This new model of care really is a team effort, and it’s making a huge difference to patients’ lives,” said Dr. McNaughton.

Related Links
University of Queensland
Queensland Children’s Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.